Somewhat Positive News Coverage Somewhat Unlikely to Impact Seattle Genetics (NASDAQ:SGEN) Share Price
News coverage about Seattle Genetics (NASDAQ:SGEN) has been trending somewhat positive on Monday, according to Accern. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Seattle Genetics earned a coverage optimism score of 0.18 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.1003971230372 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the headlines that may have effected Accern’s rankings:
- Seattle Genetics’ Adcetris Gets EU Nod For Label Expansion (benzinga.com)
- Seattle Genetics (SGEN) Shares Cross Above 200 DMA (nasdaq.com)
- Seattle Genetics, Inc., (NASDAQ: SGEN) – Risk Factors under Consideration – Stock Watch (stocksnewstimes.com)
- Guide to Day Traders – Seattle Genetics Inc (NASDAQ: SGEN) – Alpha Beta Stock (alphabetastock.com)
- Seattle Genetics, Inc. (SGEN) to Post FY2022 Earnings of $2.55 Per Share, SunTrust Banks Forecasts (americanbankingnews.com)
SGEN has been the topic of several research analyst reports. Barclays raised Seattle Genetics from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $60.00 to $70.00 in a research report on Friday, October 20th. Zacks Investment Research downgraded Seattle Genetics from a “buy” rating to a “hold” rating in a research report on Monday, October 16th. SunTrust Banks set a $52.00 target price on Seattle Genetics and gave the stock a “hold” rating in a research report on Friday, October 27th. Cowen reiterated a “hold” rating on shares of Seattle Genetics in a research report on Sunday, October 29th. Finally, JPMorgan Chase & Co. boosted their target price on Seattle Genetics from $55.00 to $60.00 and gave the stock a “neutral” rating in a research report on Monday, October 30th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $63.76.
In related news, Director Marc E. Lippman sold 3,000 shares of the company’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $58.07, for a total value of $174,210.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Clay B. Siegall sold 18,832 shares of the company’s stock in a transaction on Friday, November 10th. The shares were sold at an average price of $58.00, for a total value of $1,092,256.00. The disclosure for this sale can be found here. Insiders sold 157,210 shares of company stock worth $9,094,911 over the last 90 days. Company insiders own 34.70% of the company’s stock.
About Seattle Genetics
Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).
Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.